U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Colorectal Neuroendocrine Carcinoma

MedGen UID:
474240
•Concept ID:
C3272607
•
Neoplastic Process
Synonyms: Colorectal NEC; Colorectal NEC G3; Large Intestinal Neuroendocrine Carcinoma

Definition

An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon or rectum. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma. [from NCI]

Professional guidelines

PubMed

Pathologic differential diagnosis of metastatic carcinoma in the liver.
Park JH, Kim JH
Clin Mol Hepatol 2019 Mar;25(1):12-20. Epub 2018 Oct 5 doi: 10.3350/cmh.2018.0067. PMID: 30300991Free PMC Article
Liver Ablation: Best Practice.
Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr
Radiol Clin North Am 2015 Sep;53(5):933-71. doi: 10.1016/j.rcl.2015.05.012. PMID: 26321447Free PMC Article
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U
Ann Oncol 2013 Jan;24(1):152-60. Epub 2012 Sep 11 doi: 10.1093/annonc/mds276. PMID: 22967994

Recent clinical studies

Etiology

Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma.
Zhuang Y, Yu H, Chen CJ, Jian JL, Wu XY
Asian J Surg 2024 Jan;47(1):433-442. Epub 2023 Sep 29 doi: 10.1016/j.asjsur.2023.09.099. PMID: 37778975
Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
Chen L, Liu M, Zhang Y, Guo Y, Chen MH, Chen J
Clin Colorectal Cancer 2021 Jun;20(2):177-185.e13. Epub 2020 Sep 9 doi: 10.1016/j.clcc.2020.09.001. PMID: 33041225
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM
Mod Pathol 2019 Feb;32(2):290-305. Epub 2018 Sep 20 doi: 10.1038/s41379-018-0131-6. PMID: 30237525
BRAF(V600E) mutation: A promising target in colorectal neuroendocrine carcinoma.
Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A
Int J Cancer 2019 Mar 15;144(6):1379-1390. Epub 2018 Oct 30 doi: 10.1002/ijc.31828. PMID: 30144031
The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z, Yu D, Zhao S, Gao P, Song Y, Sun Y, Chen X, Wang Z
J Surg Res 2018 May;225:54-67. Epub 2018 Jan 19 doi: 10.1016/j.jss.2017.12.035. PMID: 29605035

Diagnosis

Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma.
Zhuang Y, Yu H, Chen CJ, Jian JL, Wu XY
Asian J Surg 2024 Jan;47(1):433-442. Epub 2023 Sep 29 doi: 10.1016/j.asjsur.2023.09.099. PMID: 37778975
GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V, Schmidt CE, Lennartz M, Höflmayer D, Hube-Magg C, Weidemann S, Fraune C, Büscheck F, Möller K, Bernreuther C, Simon R, Clauditz TS, Blessin NC, Bady E, Sauter G, Uhlig R, Steurer S, Minner S, Burandt E, Dum D, Marx AH, Krech T, Lebok P, Hinsch A, Jacobsen F
Pathobiology 2023;90(4):219-232. Epub 2023 Jan 17 doi: 10.1159/000527382. PMID: 36649695Free PMC Article
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, Takeuchi K, Fujita N, Nagayama S, Katayama R
Cancer Lett 2022 Sep 1;543:215799. Epub 2022 Jun 17 doi: 10.1016/j.canlet.2022.215799. PMID: 35724767
The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z, Yu D, Zhao S, Gao P, Song Y, Sun Y, Chen X, Wang Z
J Surg Res 2018 May;225:54-67. Epub 2018 Jan 19 doi: 10.1016/j.jss.2017.12.035. PMID: 29605035
Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.
Shafqat H, Ali S, Salhab M, Olszewski AJ
Dis Colon Rectum 2015 Mar;58(3):294-303. doi: 10.1097/DCR.0000000000000298. PMID: 25664707

Therapy

Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma.
Zhuang Y, Yu H, Chen CJ, Jian JL, Wu XY
Asian J Surg 2024 Jan;47(1):433-442. Epub 2023 Sep 29 doi: 10.1016/j.asjsur.2023.09.099. PMID: 37778975
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, Takeuchi K, Fujita N, Nagayama S, Katayama R
Cancer Lett 2022 Sep 1;543:215799. Epub 2022 Jun 17 doi: 10.1016/j.canlet.2022.215799. PMID: 35724767
Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
Nakano M, Shimada Y, Matsumoto Y, Saiki T, Zhou Q, Sasaki K, Moriyama M, Yoshihara K, Natsumeda M, Kuriyama Y, Takii Y, Watanabe G, Umezu H, Okuda S, Ikeuchi T, Wakai T, Saijo Y
Clin J Gastroenterol 2022 Apr;15(2):413-418. Epub 2022 Feb 8 doi: 10.1007/s12328-022-01599-4. PMID: 35133626
BRAF(V600E) mutation: A promising target in colorectal neuroendocrine carcinoma.
Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A
Int J Cancer 2019 Mar 15;144(6):1379-1390. Epub 2018 Oct 30 doi: 10.1002/ijc.31828. PMID: 30144031
The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z, Yu D, Zhao S, Gao P, Song Y, Sun Y, Chen X, Wang Z
J Surg Res 2018 May;225:54-67. Epub 2018 Jan 19 doi: 10.1016/j.jss.2017.12.035. PMID: 29605035

Prognosis

Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH, Hsu CY, Yau Li AF, Liang WY
Hum Pathol 2024 Mar;145:80-85. Epub 2024 Feb 27 doi: 10.1016/j.humpath.2024.02.012. PMID: 38423221
Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma.
Zhuang Y, Yu H, Chen CJ, Jian JL, Wu XY
Asian J Surg 2024 Jan;47(1):433-442. Epub 2023 Sep 29 doi: 10.1016/j.asjsur.2023.09.099. PMID: 37778975
Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
Chen L, Liu M, Zhang Y, Guo Y, Chen MH, Chen J
Clin Colorectal Cancer 2021 Jun;20(2):177-185.e13. Epub 2020 Sep 9 doi: 10.1016/j.clcc.2020.09.001. PMID: 33041225
BRAF(V600E) mutation: A promising target in colorectal neuroendocrine carcinoma.
Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A
Int J Cancer 2019 Mar 15;144(6):1379-1390. Epub 2018 Oct 30 doi: 10.1002/ijc.31828. PMID: 30144031
The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z, Yu D, Zhao S, Gao P, Song Y, Sun Y, Chen X, Wang Z
J Surg Res 2018 May;225:54-67. Epub 2018 Jan 19 doi: 10.1016/j.jss.2017.12.035. PMID: 29605035

Clinical prediction guides

Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma.
Zhuang Y, Yu H, Chen CJ, Jian JL, Wu XY
Asian J Surg 2024 Jan;47(1):433-442. Epub 2023 Sep 29 doi: 10.1016/j.asjsur.2023.09.099. PMID: 37778975
Resection of primary lesion with chemotherapy improves the survival of patients with metastatic colorectal neuroendocrine carcinoma.
Wang Q, Yin R, Tang W, Li C, Zheng H, Zhang X, Jin X, Ying M, Fu J
Zhejiang Da Xue Xue Bao Yi Xue Ban 2022 Nov 25;51(5):594-602. doi: 10.3724/zdxbyxb-2021-0387. PMID: 36581574Free PMC Article
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, Takeuchi K, Fujita N, Nagayama S, Katayama R
Cancer Lett 2022 Sep 1;543:215799. Epub 2022 Jun 17 doi: 10.1016/j.canlet.2022.215799. PMID: 35724767
Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
Nakano M, Shimada Y, Matsumoto Y, Saiki T, Zhou Q, Sasaki K, Moriyama M, Yoshihara K, Natsumeda M, Kuriyama Y, Takii Y, Watanabe G, Umezu H, Okuda S, Ikeuchi T, Wakai T, Saijo Y
Clin J Gastroenterol 2022 Apr;15(2):413-418. Epub 2022 Feb 8 doi: 10.1007/s12328-022-01599-4. PMID: 35133626
The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z, Yu D, Zhao S, Gao P, Song Y, Sun Y, Chen X, Wang Z
J Surg Res 2018 May;225:54-67. Epub 2018 Jan 19 doi: 10.1016/j.jss.2017.12.035. PMID: 29605035

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...